Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	61.86	115.85	118.37	234.2	118.72	147.7
Short-Term Investments	486.32	480.22	217.63	128.6	622.2	220.31
Cash & Short-Term Investments	548.18	596.07	336	362.79	740.92	368.01
Cash Growth	3.62%	77.40%	-7.38%	-51.03%	101.33%	-12.64%
Receivables	316.34	308.46	234.21	231.07	90.98	97.73
Inventory	181.51	141.86	127.6	100.12	53.91	60.75
Prepaid Expenses	76.65	38.95	48.61	45.02	40.48	28.27
Total Current Assets	1,123	1,085	746.42	739.01	926.29	554.76
Property, Plant & Equipment	71.52	75.04	74.94	75.57	8.79	10.59
Goodwill	416.82	416.82	416.82	409.05	-	-
Other Intangible Assets	366.31	401.83	472.88	546.65	-	-
Long-Term Deferred Tax Assets	20.21	3.86	4.39	44.43	155.43	-
Other Long-Term Assets	56.37	80.6	17.82	26.8	13.91	14.57
Total Assets	2,054	2,063	1,733	1,842	1,104	579.92
Accounts Payable	18.69	10.25	11.82	17.69	1.54	1.93
Accrued Expenses	115.59	121.8	100.68	97.66	22.17	19.08
Current Portion of Long-Term Debt	-	-	-	13.33	89.42	397.23
Current Portion of Leases	-	7.05	-	2.1	2.28	1.4
Current Unearned Revenue	-	-	-	-	1.75	1.75
Total Current Liabilities	134.28	139.1	112.49	130.79	117.15	421.39
Long-Term Debt	1,509	1,506	1,499	1,493	787.26	-
Long-Term Leases	28.97	23.65	32.2	32.69	0.54	3.47
Long-Term Unearned Revenue	-	-	-	-	2.53	4.03
Other Long-Term Liabilities	48.8	31.11	5.52	15.47	-	-
Total Liabilities	1,721	1,700	1,649	1,672	907.48	428.88
Common Stock	0.12	0.12	0.13	0.14	0.14	0.14
Additional Paid-In Capital	-	-	2.41	27.37	256.35	625.48
Retained Earnings	361.03	359.87	90.55	143.22	-58.91	-474.59
Comprehensive Income & Other	-28.4	3.83	-9.28	-0.92	-0.62	0.02
Shareholders' Equity	332.75	363.82	83.81	169.8	196.95	151.05
Total Liabilities & Equity	2,054	2,063	1,733	1,842	1,104	579.92
Total Debt	1,538	1,537	1,531	1,541	879.49	402.1
Net Cash (Debt)	-989.89	-940.43	-1,195	-1,178	-138.57	-34.08
Net Cash Per Share	-7.76	-7.27	-8.91	-8.38	-0.94	-0.24
Filing Date Shares Outstanding	116.97	123.15	126.82	135.37	137.7	135.21
Total Common Shares Outstanding	117.62	123.14	126.77	135.15	137.5	134.97
Working Capital	988.39	946.24	633.93	608.22	809.14	133.38
Book Value Per Share	2.83	2.95	0.66	1.26	1.43	1.12
Tangible Book Value	-450.38	-454.83	-805.89	-785.9	196.95	151.05
Tangible Book Value Per Share	-3.83	-3.69	-6.36	-5.81	1.43	1.12
Machinery	61.46	59.28	50.78	43.13	18.26	17.25
Leasehold Improvements	7.35	7.01	6.99	6.73	1.63	1.63
Order Backlog	-	99.9	-	-	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q